BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Sensys developed a non-invasive blood glucose monitor that used near infrared diffuse reflectance spectroscopy. The technology was designed to provide a painless method to collect data for proactive use in controlling diabetes.
Sensys Medical
Chandler, AZ
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.